Last reviewed · How we verify
Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients
A randomized, double-blind, placebo-controlled phase II exploratory clinical trial to evaluate the efficacy and safety of Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with COVID-19.
Details
| Lead sponsor | Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd. |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 180 |
| Start date | Thu Dec 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Nov 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- COVID-19
Interventions
- Human COVID-19 immunoglobulin (pH4) for intravenous injection
- Placebo
Countries
United Arab Emirates